Clinical trials: Non Alcoholic Fatty Liver
Healthy
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.
- Trial name
- NCT03597217
- Testing
- PF-05221304
- Where
- Japan
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis
Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single-and multiple-oral doses of ZSP0678 on fasted condition, and characterize PK of ZSP0678 on an empty stomach (fasted condition) and…
- Trial name
- NCT04137055
- Testing
- ZSP0678-10mg, ZSP0678-30mg, ZSP0678-60mg
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
NASH - Nonalcoholic Steatohepatitis
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Trial name
- HM-TRIA-201 (NCT04505436)
- Testing
- HM15211
- Where
- 60 sites in United States, South Korea
- Volunteers
- 215 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included.
- Trial name
- SDOI (NCT05176132)
- Testing
- Life style intervention (dietician+ physiotherapist), Self management, No intervention
- Where
- Denmark
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Claus Bogh Juhl
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
Effects of Wheat-based diet vs. ATI-free diet on NASH
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2, Hyperlipidemias
- Trial name
- NASH-ATI (NCT04066400)
- Testing
- Nutritional Intervention
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Johannes Gutenberg University Mainz
Fatty Liver
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)
Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal liver tests. It is closely linked to health problems like obesity and diabetes.
- Trial name
- NCT02363309
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Insulin Resistance, Prediabetic State
Pancreatic Clamp in NAFLD
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp…
- Conditions
- Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05724134
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Columbia University
NAFLD, Diabetes Mellitus, Type 2
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes
The overall aim of this study is to investigate the long-term impact of a customized diet aimed at reducing liver fat specifically and a healthy Nordic diet on ectopic fat (liver, pancreatic and visceral) and cardiometabolic risk…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, PreDiabetes
- Trial name
- NAFLDiet (NCT04527965)
- Testing
- Customized diet to reduce liver fat, Healthy Nordic diet, Control
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Diabetes Type 2, NAFLD
Follow-up of NAFLD Patients With MRI-PDFF
The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an…
- Trial name
- NCT04910178
- Testing
- Empagliflozin 25 MG, Ursodeoxycholic acid, Pentoxifylline 400 MG
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Asmaa Abdelfattah Elsayed
Nonalcoholic Steatohepatitis
Dapagliflozin Efficacy and Action in NASH
This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.
- Trial name
- DEAN (NCT03723252)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diabetes, Fatty Liver
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Background: Vitamin E is an antioxidant that reduces the damaging effects of oxygen in the body. Most American men (90%) and women (96%) do not get enough vitamin E from their diets; however, the amount of vitamin E needed by the…
- Conditions
- Diabetes, Fatty Liver, Obesity, Healthy Volunteers
- Trial name
- NCT00862433
- Testing
- Alpha tocopherol, Vitamin E, Vitamin C
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02581085
- Testing
- Tocotrienol (TCT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Chandan Sen
Nonalcoholic Steatohepatitis, Metabolic Syndrome
The Role of Leptin Receptors in NASH
NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis.
- Trial name
- NASH (NCT00583999)
- Testing
- no interventions, only regular blood-draw
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
NAFLD
NAFLD in Patient of Hypothyroidism
Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population.
- Trial name
- NCT05813301
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on…
- Trial name
- NCT07407634
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) includes benign hepatic simple steatosis (SS) and steatohepatitis (NASH), which is characterised by inflammation leading to fibrosis and cirrhosis.
- Trial name
- NCT01856465
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Johane Allard
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.